This organization files Form 990, which has no section for application policy. Its filings cannot say either way.
The latest filing we hold carries no statement about applications. That is not the same as closed: public-charity Form 990s have no field for it, and many foundations leave the section blank.
Grants paid by year
Total assets by year
Where the money went · FY2023
Form 990 splits expenses into program services, management and fundraising. The split is self-reported, and a grantmaker, a research institute and a direct-service nonprofit book the same work differently. A line the return does not carry reads "not available"; it is never counted as zero.
| Year | Form | Revenue | Expenses | Grants paid | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2023 | 990 | $37,725,207 | $34,633,548 | $26,431,117 | $33,488,279 | $31,760,955 |
| FY2022 | 990 | $40,708,245 | $30,613,014 | $23,431,727 | $30,192,784 | $28,458,610 |
| FY2021 | 990 | $26,572,727 | $23,165,275 | $17,719,354 | $23,967,152 | $18,200,501 |
| FY2020 | 990 | $22,899,223 | $21,006,379 | $14,050,077 | $16,427,042 | $14,795,453 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 96% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| BOSTON CHILDRENS HOSPITALBOSTON, MA | NEUROIMFLAMMATION CONSORTIUM: UNDERSTANDING THE CONSEQUENCES OF NON-CODING AD RISK ALLELES ON MICROGLIA FUNCTION | $300,000 | 2020 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| Margaret Smith | CEO (AS OF 10/23) | 40.00 | $321,513 |
| Henry Mccance | CHAIR | 5.00 | $0 |
| Jacqueline Morby | DIRECTOR | 5.00 | $0 |
| Robert Greenhill | DIRECTOR |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| WASHINGTON UNIVERSITY ST LOUISST LOUIS, MO |
| APOE CONSORTIUM: UNDERSTANDING THE EFFECT OF APOE ON TAU-MEDIATED NEURODEGENERATION (YEAR 3) |
| $300,000 |
| 2020 |
| BOSTON CHILDREN'S HOSPITALBOSTON, MA | NIC: UNDERSTANDING THE CONSEQUENCES OF NON-CODING AD RISK ALLELES ON MICROGLIA FUNCTION | $300,000 | 2022 |
| THE UNIVERSITY OF CALIFORNIA SAN DIEGOLA JOLLA, CA | CONTINUING STUDIES OF THE EFFECTS OF GSM 776890 ADMINISTRATION ON AMYLOID SPECIES AND MICROGLIOSIS IN OLDER ALZHEIMER'S MODEL MICE | $291,374 | 2021 |
| BRIGHAM AND WOMEN'S HOSPITALBOSTON, MA | MBC: HARNESSING DIET-MICROBE INTERACTIONS TO PREVENT ALZHEIMER'S DISEASE PATHOGENESIS | $287,500 | 2023 |
| WASHINGTON UNIVERSITYST LOUIS, MO | MBC: THE ROLE OF GUT MICROBIAL METABOLISM IN TAU-MEDIATED NEURODEGENERATION | $287,500 | 2023 |
| MASSACHUSETTS GENERAL HOSPITALCHARLESTOWN, MA | NIC: BIOMARKER TOOL DEVELOPMENT IN CAF NEUROIMMUNE CONSORTIUM | $287,500 | 2022 |
| WEILL CORNELLNEW YORK, NY | BEE: BIOCHEMICAL AND FUNCTIONAL ANALYSIS OF CSF AND LYMPH FOLLOWING CHANGES IN BRAIN FLUID DYNAMICS | $287,500 | 2023 |
| MASSACHUSETTS GENERAL HOSPITALBOSTON, MA | MBC: MICROBIAL PROFILING OF HUMAN BRAIN AND GUT MICROBIOMES IN ALZHEIMER'S DISEASE | $287,500 | 2023 |
| BRIGHAM AND WOMEN'SBOSTON, MA | APOE CONSORTIUM: APOE4-MEDIATED DYSFUNCTION OF CD8 T CELL-MICROGLIA CROSSTALK IN ALZHEIMERS DISEASE | $287,500 | 2022 |
| BRIGHAM AND WOMEN'S HOSPITALBOSTON, MA | APOE CONSORTIUM: APOE4-MEDIATED DYSFUNCTION OF CD8 T CELL-MICROGLIA CROSSTALK IN ALZHEIMER'S DISEASE | $287,500 | 2023 |
| BOSTON UNIVERSITYBOSTON, MA | APOE CONSORTIUM: MODULATION OF SELECTIVE NEURONAL VULNERABILITY IN ALZHEIMER'S DISEASE BY APOE | $287,500 | 2023 |
| UNIVERSITY OF CALIFORNIA SAN DIEGOLA JOLLA, CA | NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION | $287,500 | 2023 |
| UNIVERSITY OF CALIFORNIA SAN DIEGOLA JOLLA, CA | BEE: IDENTIFYING THE BLOOD-BRAIN BARRIER CHANGES DURING ALZHEIMERS DISEASE | $287,500 | 2022 |
| UNIVERSITY OF CALIFORNIA SAN DIEGOLA JOLLA, CA | BEE: IDENTIFYING THE BLOOD-BRAIN BARRIER CHANGES DURING ALZHEIMER'S DISEASE | $287,500 | 2023 |
| WEILL CORNELLNEW YORK, NY | BEE: BIOCHEMICAL AND FUNCTIONAL ANALYSIS OF CSF AND LYMPH FOLLOWING CHANGES IN BRAIN FLUID DYNAMICS | $287,500 | 2022 |
| UNIVERSITY OF CALIFORNIA IRVINEIRVINE, CA | NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS | $287,493 | 2023 |
| MASSACHUSETTS GENERAL HOSPITALBOSTON, MA | ADTC: HOW DO SOLUBLE TAU SPECIES REPLICATE? | $287,169 | 2023 |
| UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTERDALLAS, TX | ADTC: ROLE OF VCP/P97 IN TAU PRION REPLICATION | $287,000 | 2023 |
| UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTERDALLAS, TX | ADTC: THE ROLE OF VCP/P97 IN TAU PRION REPLICATION | $287,000 | 2022 |
| MASSACHUSETTS GENERAL HOSPITALCHARLESTOWN, MA | ADTC: HOW DO SOLUBLE TAU SPECIES REPLICATE? | $286,595 | 2022 |
| NORTHWESTERN UNIVERSITYCHICAGO, IL | ADTC: THE ROLE OF A-INDUCED MEMBRANE DAMAGE IN TAU PATHOLOGY | $286,448 | 2023 |
| NORTHWESTERNCHICAGO, IL | ADTC: THE ROLE OF A-INDUCED MEMBRANE DAMAGE IN TAU PATHOLOGY | $286,357 | 2022 |
| THE UNIVERSITY OF CALIFORNIA SAN DIEGOLA JOLLA, CA | COMPREHENSIVE ANALYSES OF CHRONIC EFFICACY STUDIES WITH GSM 776890 FOR SUBMISSION OF THE PRE-IND BROCHURE TO THE FDA PRIOR TO PRE-IND MEETING AND IND FILING FOR THE SAD/MAD PHASE I SAFETY/TOXICITY AND ULTIMATELY FOR PHASE II AND PHASE III EFFICACY CLINICAL TRIALS TO SUPPORT THE NDA | $259,366 | 2020 |
| MASSACHUSETTS GENERAL HOSPITALBOSTON, MA | FUNCTIONAL CHANGES TO CEREBROSPINAL FLUID IMMUNE CELLS RESULTING FROM BACILLUS CALMETTE-GURIN (BCG) VACCINATION IN OLDER ADULTS WITH AND WITHOUT ALZHEIMER'S DISEASE | $258,750 | 2023 |
| 5.00 |
| $0 |
| Richard Birnbaum | DIRECTOR (AS OF 7/23) | 5.00 | $0 |
| Jeffrey Morby | DIRECTOR (DECEASED 9/23) | 20.00 | $0 |
| Timothy Armour | FORMER PRESIDENT & CEO (TO 09/23) | 40.00 | $350,862 |
| Laurel Lyle | SECRETARY & VP BOARD RELAT | 30.00 | $113,594 |
| Phyllis Rappaport | TREASURER | 2.00 | $0 |
| Josephine Antonellis | CHIEF FINANCIAL OFFICER (AS OF 8/23) | 30.00 | $150,986 |
| Katharine Herman | EVP DEVELOPMENT | 40.00 | $405,657 |
| Barbara Chambers | EVP MARKETING & COMM. | 40.00 | $254,908 |
| Daniel Harper | SENIOR PHILANTHROPIC ADVISOR | 40.00 | $181,380 |
| Mahua Dasgupta | SR. PHILANTROPIC ADVISOR | 40.00 | $168,942 |
| John Slattery | SVP MAJOR GIFTS | 40.00 | $190,709 |
| Kelly Westerhouse | VP LEADERSHIP GIVING | 40.00 | $155,421 |
| Lisa Rand | VP MARKETING & COMM. | 40.00 | $193,830 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990 · FY2024 · period ending Dec 31, 2024IRS bulk XML
Filing id 202531289349302248
Form 990 · FY2023 · period ending Dec 31, 2023IRS bulk XML
Filing id 202421229349300027
Form 990 · FY2022 · period ending Dec 31, 2022
Filing id 202331259349301933
Form 990 · FY2021 · period ending Dec 31, 2021
Filing id 202241309349304019
Form 990 · FY2020 · period ending Dec 31, 2020
Filing id 202141319349300914
Form 990 · FY2019 · period ending Dec 31, 2019
Filing id 202041559349301614
Form 990 · FY2018 · period ending Dec 31, 2018
Filing id 201901159349300235
Form 990 · FY2017 · period ending Dec 31, 2017
Filing id 201831219349300108
Form 990 · FY2016 · period ending Dec 31, 2016
Filing id 201711099349300741
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.